Drugs / CT-P17
CT-P17
English name adalimumab
also known as
adalimumab
Monoclonal antibody targets TNF via inhibition
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03970824 | May → Nov 2019 | — | Celltrion | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05495568 | Nov 2022 → Aug 2023 | psoriasis | Celltrion | Completed | No outcome recorded |
| Phase 3 | NCT03789292 | Nov 2018 → Oct 2019 | rheumatoid arthritis | Celltrion | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04295356 Comparator | Jun → Nov 2019 | — | Celltrion | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-P17 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04295356 ↗ |
| Known as | adalimumab | “Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects.” PMID 33822406 ↗ May 20211“CT-P17 is a recombinant human monoclonal antibody containing the active ingredient adalimumab (human TNF-α blocker).” NCT05495568 ↗ |
| Action | Inhibit | “human TNF-α blocker” NCT05495568 ↗ |
| Modality | Monoclonal antibody | “CT-P17, containing the active ingredient adalimumab, is a recombinant humanized monoclonal antibody” NCT03789292 ↗ |
| Route | Subcutaneous | “receive a single 40 mg (100 mg/ml) subcutaneous injection of CT-P17, US-adalimumab, or EU-adalimumab” PMID 33503313 ↗ Mar 2021 |
| Target | TNF | “human TNF-α blocker” NCT05495568 ↗ |